weight loss drug
Coverage of weight loss drug in the Nexus archive.
- Amgen is raising its outlook after beating earnings and dropping a weight loss drug
Amgen has increased its full-year revenue forecast to $38.2 billion–$39.4 billion following a 10% rise in second-quarter revenue to $10.1 billion. The company also announced the discontinuation of a weight loss drug.
- Eli Lilly is pushing its next-generation weight loss drug approval filing to early 2027
Eli Lilly is delaying the FDA approval filing for its next-generation triple-hormone weight loss drug from this year to early 2027. The company had previously indicated it could seek approval as early as 2024.
- The Thriving Black Market for a Powerful Weight Loss Drug
Retatrutide, the most powerful weight-loss drug in development, is not expected to enter the U.S. market before next year but has already appeared on the black market.
- Eli Lilly says next-generation weight loss drug clears crucial obesity trial
Eli Lilly announces that its next-generation weight loss drug retatrutide has successfully passed a crucial obesity trial. The injection works through a different mechanism than existing weight loss treatments and brings the company closer to filing for regulatory approval.
- People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says
Eli Lilly's experimental weight loss drug demonstrated significant results with participants losing up to 85 pounds, according to the company. The pharmaceutical company is advancing its drug candidate as a competitor in the growing weight loss medication market.
- The real reason your Mounjaro has stopped working: DR PHILIPPA KAYE reveals diet supplement that can turbocharge the jabs, the part of the body you MUST inject and why it may be time to switch to a different weight loss drug
Dr. Philippa Kaye discusses why Mounjaro may lose effectiveness, recommending a diet supplement to enhance its results, emphasizing proper injection sites, and suggesting potential alternatives for weight loss.